The survival of axotomized RGCs was increased by intravitreal NT-4/5 given by repeated injections or osmotic minipumps, but the effects were less complete than predicted. Compared to a single injection of the neurotrophin on day 0, second injections on days 3 or 7 only sustained an additional 10-20% of the RGCs on day 10. Minipumps augmented RGC survival up to 4-fold (50%) at 2 weeks but most RGCs were lost by 1 month. Thus, specific neurotrophins can rescue many RGCs soon after injury but long-term neuronal survival may require a better understanding of changes in neurotrophin receptors and interactions with other molecules.
Introduction
After axotomy near the eye, retinal ganglion cell (RGC) death by apoptosis begins on day 4, and leads to the rapid loss of most RGCs: only 50% remain on day 7, 25% on day 10, and less than 10% on day 14 [2] . Single intravitreal injections of BDNF [18] or NT-4/5 [22] on the day of axotomy delay the onset of RGC death by approximately 3 days but the effect is not maintained; all of the neurotrophin-treated RGCs survive to day 7 (100%), decreasing to approximately 60% by day 10, and to 20 -40% by day 14. Additional examples of the transientness of the effects of BDNF or NT-4/5 on the survival of injured neurons have been documented in neonatal animals after axotomy of RGCs [6] or spinal motor neurons [8, 23, 26] .
The massive early loss of RGCs that follows optic nerve (ON) transection is also delayed by the attachment of PN grafts [28] or by the application of peripheral nerve extracts [19] . The effect of attaching PN grafts, which presumably provide injured RGCs with trophic molecules critical for survival, lasts longer than the effect of a single neurotrophin administration, but also declines between 1 and 3 months. On the other hand, the reconnection of RGCs with their normal targets in the superior colliculus (SC) may assure the survival of these neurons. Indeed, when the retina and the SC are reconnected by a peripheral nerve (PN) graft, the numbers of regenerated RGC axonal terminals remains stable between 4-6 and 8-10 months after axotomy and graft placement [4] . Thus, axotomy-induced RGC loss appears to be preventable. Moreover, most of these cells might persist throughout the life of the animal if the survival of the injured RGCs could be maintained until their axons were allowed to regenerate and form synapses in the SC.
The aim of the present experiments was to determine if a more prolonged exposure of axotomized RGCs to NT-4/5, a neurotrophin that shares many homologies with BDNF [3, 12, 14] , would lengthen their survival beyond the few days possible with single injections. Because their numbers can be precisely analysed, RGCs are a particularly useful neuronal population in which to study the effects of repeated or prolonged neurotrophin administration.
Methods

Surgical procedures
Surgical procedures were performed in adult female Sprague-Dawley rats (180 -200 g) anesthetized with intraperitoneal chloral hydrate (7%) in accordance with the principles outlined in ''The Guide to the Care and Use of Experimental Animals'' of the Canadian Council on Animal Care. Prior to experimental manipulations, Fluorogold ® [24] was applied to the surface of both superior colliculi to label the cell bodies of RGCs by retrograde transport [2] . One week later, the left optic nerve (ON) was transected with microscissors, leaving a 0.5-mm stump attached to the globe. Preservation of the retinal blood supply was confirmed by microscopic examination of the retina through the dilated pupil.
Administration of NT-4/5
To determine the effect of single injections, 5 ml of human recombinant NT-4/5 (E. coli-derived; provided by Regeneron Pharmaceuticals, Inc.) were injected slowly into the vitreous chamber of the eye at the time of ON transection. The tip of the needle was inserted into the vitreous chamber by a posterior approach through the sclera and retina at a distance of approximately 3 mm from the ON into the dorso-temporal quadrant (Fig. 1) . After the injection, the hole through the sclera was sealed with Histoacryl tissue glue. Control rats received an intravitreal injection of 5 ml of vehicle (phosphate-buffered saline, PBS).
In groups of four to six rats, 3 mg of NT-4/5 in 5 ml PBS or 5 ml of PBS alone were given in the following sets of experiments: (i) single injections at the time of ON transection with measurement of RGC densities 7, 10, 14, 21 and 28 days later; (ii) single injections 7 or 3 days before, or 3 or 6 days after, ON transection with determinations of RGC densities 10 days after ON transection (day 10); (iii) a first injection at the time of ON transection and a second injection on day 3 or day 7 with measurement of RGC densities on day 10 or day 14.
To determine the effect of prolonged neurotrophin administration on RGC survival, NT-4/5 was delivered to the vitreous chamber of the eye from an osmotic mini-pump (Alzet c 2002) filled with NT-4/5 (0.1 mg/ ml) or PBS and placed in a subcutaneous pocket. The osmotic mini-pump delivered either NT-4/5 (n= 8) or PBS (n= 9) at approximate rates of 0.5 ml/h for 14 days. In other rats, the pumping rate was reduced by 50% to deliver either NT-4/5 (n= 4) or PBS (n =3) at approximately 0.25 ml/h for 28 days.
Tissue processing
At the end of the experimental period, the rats were deeply anesthetized with chloral hydrate (900 mg/kg) and perfused through the heart with 50-100 ml of 0.9% normal saline followed by 200-300 ml of 4% paraformaldehyde in 0.1 M phosphate buffer. The left (experimental) and right (internal control) eyes were removed and the retinas flat-mounted.
Quantitation of RGC sur6i6al
Using a fluorescence microscope, the number of surviving RGCs in experimental and control retinas were determined by counting the number of Fluorogold ® -labelled neurons in three standard areas of each retinal quadrant at 1, 2 and 3 mm from the optic disc, for a total area of 0.965 mm 2 [2, 29] . RGC survival data from each group of animals are presented as the mean densities (RGCs/mm 2 ) and standard deviations (mean9 S.D.). The results were analyzed with the SigmaStat program, as previously described [18] .
Results
Optimum dose of NT-4/5
To determine the optimum amount of NT-4/5 to enhance RGC survival, 5 ml of NT-4/5 in doses ranging from 0 to 0.84 mg/ml were administered at the time of axotomy (day 0) in groups of four to six rats. Increasing amounts of NT-4/5 resulted in dose-dependent increments in RGC survival that peaked at 3 mg. A higher dose (4.2 mg) did not further increase RGC survival 10 days after axotomy (Fig. 2) . NT-4/5 had its most potent survival effect when 3.0 mg (0.6 mg/ml) was given; there was no additional increase in survival when 4.2 mg of NT-4/5 was given. When only 0.05 mg of NT-4/5 was given, RGC survival did not differ significantly from that after a control injection. administration of PBS. However, when NT-4/5 was administered at 3 days before or 3 days after axotomy, nearly 50% of the RGCs survived (Fig. 5) . Although the effect was still statistically significant, fewer RGCs survived when the NT-4/5 was given 7 days before (33%) or 6 days after (42.6%). These results suggest that the injury to the RGCs had not blocked the capacity of most of these neurons to respond to the neurotrophin.
Prolonged neurotrophin administration
With control osmotic minipumps that contained PBS, the density of surviving RGCs at 2 weeks was 2719 97 (mean 9 S.D.) or 12% of the original RGC population compared to 1149 30 for the retinas without minipumps (Fig. 6) . The RGC densities for individual retinas from the groups of animals treated with NT-4/5 via the osmotic mini-pumps (Fig. 6 ) fell into two ranges: in three of the eight animals with NT-4/5 pumps for 2 weeks, RGC densities were 7 or more standard deviations beyond the mean for the PBStreated group. In these three retinas, nearly 50% of the normal RGCs were preserved 2 weeks after injury. In the other five retinas, RGC densities were within 3 standard deviations of this mean.
At 4 weeks, the mean RGC density in the PBStreated retinas was 91933 (4%). In two of the four NT-4/5-treated retinas, the RGC densities were more than 10 standard deviations above the mean for the control retinas; RGC densities in the other two retinas were not significantly different from the mean for the control retinas (Fig. 6) .
Thus, in some treated retinas, the continuous infusion of NT-4/5 had a substantial effect on RGC survival. The variability of the responses observed in these animals may have been due to technical difficulties in maintaining a patent cannula within the small vitreous chamber of the rat eye, a possibility that could not be independently assessed. Vehicle-containing minipumps slightly increased this survival (Fig. 6) , suggesting that injury-related trophic cytokines [30] were released by the intravitreal placement of the canula.
RGC sur6i6al after two injections of NT-4/5
Second injections of NT-4/5 on day 3 only increased the density of surviving RGCs by approximately 10% of the RGC population (Fig. 7) , an effect that was not statistically significant from that of single injections on day 0 (14849 223 vs. 1371923 cells/mm 2 ; P\0.05, t-test). When the second injections were given on day 7 (Figs. 4 and 7) , 16% more RGCs survived on day 10 (17239 172 vs. 13719 23; P= 0.002, Mann-Whitney rank sum test) and 18% more on day 14 (7969 81 vs. 3919 52; PB 0.001, t-test) but the rate of RGC loss did not change (Fig. 4). 
Single NT-4/5 injection
In uninjured retinas, the density of FG-labelled RGCs was 22159 69/mm 2 . As previously reported [2] , RGC numbers were maintained for the first 4 days after ON transection but decreased rapidly over the next week (Fig. 3) . Less than 10% of the RGCs (114 912) survived by 2 weeks and, by 28 days, fewer than 2% of these neurons were still present (Fig. 4) .
After administration of NT-4/5 at the time of axotomy, RGC densities remained normal for 7 days (Figs.  3 and 4) . Thereafter, the rate of RGC loss parallelled that of the untreated retinas. By day 14, RGC survival in the NT-4/5-treated retinas remained statistically greater (3919 52/mm 2 ; 17.7%) than after a PBS injection (1819 51; 8.2%) or axotomy alone (1149 12; 5.1%). By 21 days, when only 4.6% of the RGCs survived, the effect of the single administration of NT-4/5 was completely dissipated.
NT-4/5 administered before or after axotomy
The optimum amount of NT-4/5 (3 mg) or an equal volume of PBS (5 ml) was administered before (3 or 7 days) or after axotomy (3 or 6 days). RGC survival in these retinas at 10 days was compared to that seen when NT-4/5 was administered at the same time as the ON transection. The greatest survival effect was observed when NT-4/5 was administered at the time of axotomy (62%), compared to (22.9%) following the The bars depict the mean RGC density for the control groups that were normally distributed. In three animals with NT-4/5 pumps for 2 weeks, and in two with the pumps for 4 weeks, the density of surviving RGCs was more than 7 standard deviations beyond the mean for the PBS-treated groups.
Discussion
It is well known that the administration of specific neurotrophins can prevent the acute loss of many classes of injured neurons in vivo [1] . In the rat eye, for example, the death of axotomized RGCs, nearly all of which express TrkB [13] , can be delayed for approximately 3 days by intravitreal injections of BDNF or NT-4/5 [18, 22] . Subsequently, the rates of RGC loss paralleled those observed in the untreated eyes.
In the present experiments, we investigated the survival of axotomized RGCs after administration of NT- At all times, the RGC densities were significantly greater in the NT-4/5-treated retinas than in the PBS-treated retinas. There were no significant differences in RGC densities among the PBS-treated groups. The greatest mean survival occurred when NT-4/5 was given at the time of axotomy. 4/5 to determine if a more prolonged exposure of the retina to this TrkB ligand would significantly extend the survival of these injured CNS neurons beyond the few days possible with single injections. Because intraventricular administration of another neurotrophin, nerve growth factor (NGF), appeared to prevent the loss of all basal forebrain neurons after fimbria-fornix lesions for periods of 2 or 4 weeks (e.g. Refs. [9, 21, 32] ), we first used osmotic minipumps to deliver NT-4/5 intravitreally in adult rats in which one ON had been transected. It was anticipated that this approach would extend the early effects of a single intravitreal injection and prolong the viability of nearly all the axotomized RGCs for more than 3 days. However, the administration of NT-4/5 by osmotic minipump only augmented the proportions of injured RGCs that survived axotomy to a maximum of 50% of the RGC population at 2 weeks and 30% at 4 weeks. Although this level of survival was substantially greater than the 5 and 3% of the axotomized RGCs that survived at 2 and 4 weeks with no treatment, the prolonged administration with the minipumps failed to sustain most of the neurons at 2 or 4 weeks, as would have been expected if the response of the axotomized RGCs to NT-4/5 had been similar to that of injured cholinergic CNS neurons to NGF.
These experiments did not reveal whether the failure to obtain greater RGC survival was due to limited neurotrophin availability or to changes in neuronal responsiveness because the amount and duration of NT-4/5 delivery with the minipumps could not be determined. To address these issues more directly, we compared the effect of single and double intravitreal injections of NT-4/5. Since the loss of 50% of the RGC population by 7 days after ON transection [2] can be prevented by a single intravitreal injection of NT-4/5 or BDNF on the day of axotomy (day 0), it was predicted that a second injection would extend the effects of NT-4/5 and preserve all RGCs for at least an additional 3 days (i.e. until day 10). However, when such second injections were given on day 3 or day 7, 78% or less of the RGC population survived on day 10. Thus, the predicted effect of the second injection of neurotrophin fell short by approximately 22% of the RGC population. This was a substantial difference between the predicted and actual RGC survival; 38% of the RGC population die between day 7 and day 10 after the single injection of NT-4/5, so the second injection failed to rescue approximately 60% of the neurons at risk.
Possible explanations
Although the temporary effects of single injections of BDNF [18] or NT-4/5 could have been due to a limited availability of the neurotrophin, the failure of the second injections to achieve the same level of short-term survival predicted by the first injection suggests that mechanisms other than neurotrophin availability were involved. This possibility is also supported by the results of other experiments in which a more prolonged intraretinal expression of the BDNF gene by the introduction of an adenoviral vector into Mü ller glial cells also prevented the early loss of RGCs but failed to increase the number of RGCs that survived 16 days after axotomy, in a pattern of rescue that was similar to that observed after a single injection of NT-4/5 or BDNF protein [7] .
Receptor mechanisms
Possible explanations for this inability of these two neurotrophins to sustain survival of an injured population of Trk-B-expressing neurons beyond a few days are suggested by the results of in vitro experiments by other investigators. Exposure of hippocampal or cortical neurons to BDNF or NT-4/5 causes the down-regulation of trkB mRNA and protein [10, 15] . In addition, the prolonged exposure of responsive neurons to BDNF down-regulates the stimulative effects of the subsequent administration of BDNF or NT-3 on tyrosine phosphorylation [15] or phosphatidylinositol hydrolysis [31] , and the intraventricular administration of BDNF transiently abolishes the injury-induced up-regulation of BDNF mRNA within neurons of the dentate gyrus [27] . In contrast, NGF has a positive regulatory effect on its TrkA receptor [11, 16, 17] . Such differences in the responses of TrkA and TrkB to their ligands could explain the reduced effect observed in vivo after prolonged administration of NT-4/5 in the present experiments, which, to our knowledge, are the only experiments where the effect of repeated or prolonged administration of BDNF or NT-4/5 alone on neuronal survival was studied for more than 1 week after injury in adult animals.
Other possibilities
When the ON is transected in transgenic mice that overexpress the anti-apoptotic molecule, Bcl-2, approximately 65% of the axotomized RGCs survive for at least 3 months [5] . Furthermore, the long-term survival of neonatal RGCs is only possible in vitro [20] or during development [25] if multiple trophic factors are given and intracellular cAMP is augmented. It is also possible that more prolonged survival of axotomized neurons will be possible when there is a better under standing of other molecules, activity-related processes and receptor mechanisms involved in cell survival.
In summary, our studies indicate that the administration of additional neurotrophin can prolong the short-term survival of all of the injured RGCs for 3 days beyond the time of onset of post-axotomy apoptosis. However, neither these studies in the retina nor, to our knowledge, any other in vivo studies have documented quantitatively unequivocal examples of a prolonged survival of an entire population of injured neurons treated with BDNF or NT4/5. In vitro studies by other investigators suggest that the diminishing effectiveness of providing additional neurotrophins, such as BDNF, is due to altered neuronal responsiveness. It is also possible that the administration of several trophic molecules will permit the more prolonged survival of injured RGCs. Finally, because the determinants of acute and protracted cell death may be different, it remains to be proven that prolonged neurotrophin administration can protect injured neurons indefinitely. Nevertheless, it is evident that the use of the appropriate trophic molecules is an effective tool to promote the short-term survival of acutely injured neurons.
